Precision Oncology in Lung Cancer Surgery
P Bou-Samra, S Singhal - Surgical Oncology Clinics, 2024 - surgonc.theclinics.com
Background In 1912, Dr Hugh Morriston Davies first introduced the concept of an oncologic
lung resection by individual ligation of hilar vessels and suture closure of the bronchus. His …
lung resection by individual ligation of hilar vessels and suture closure of the bronchus. His …
Neuro-ophthalmic complications of modern anti-cancer drugs
JA Oskam, HV Danesh-Meyer - Graefe's Archive for Clinical and …, 2024 - Springer
Purpose Targeted cancer therapies have been responsible for a dramatic shift in treatment
strategies for cancer, and the number of drugs, classes, and indications are continually …
strategies for cancer, and the number of drugs, classes, and indications are continually …
Clinical practice guidelines for molecular tumor marker, review part 2
Y Kikuchi, H Shimada, F Yamasaki… - International Journal of …, 2024 - Springer
In recent years, rapid advancement in gene/protein analysis technology has resulted in
target molecule identification that may be useful in cancer treatment. Therefore,“Clinical …
target molecule identification that may be useful in cancer treatment. Therefore,“Clinical …
Rare Driver Mutations in Advanced, Oncogene-Addicted Non-Small Cell Lung Cancer: A North Italian, Real-World, Registry Experience
K Andrikou, P Ulivi, E Petracci, I Azzali, F Bertolini… - Diagnostics, 2024 - mdpi.com
The real-world, retrospective, NEROnE registry investigated the impact of next-generation
sequencing (NGS) in advanced non-small-cell lung cancer (NSCLC) patients (pts) at three …
sequencing (NGS) in advanced non-small-cell lung cancer (NSCLC) patients (pts) at three …
Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature
P Zhang, JH Xu, Q Wu, J Qian, S Wang - Diagnostic Pathology, 2024 - Springer
Background Crizotinib, an oral first-generation tyrosine kinase inhibitor (TKI), is superior to
systemic chemotherapy for the treatment of non-small cell lung cancer (NSCLC) with …
systemic chemotherapy for the treatment of non-small cell lung cancer (NSCLC) with …
Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC
K Arnaoutakis, Y Wan, J Elliott, M Young, Y Yin… - Advances in …, 2024 - Springer
Introduction Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are
standard first-and second-line treatment for advanced ALK+ non-small cell lung cancer …
standard first-and second-line treatment for advanced ALK+ non-small cell lung cancer …
Ficonalkib (SY-3505) in advanced ALK-positive NSCLC: a multicenter, open-label, single-arm, phase 1/2 study
Y Shi, X Hu, X Li, C Gong, K Wang, Y Li… - Journal of Thoracic …, 2024 - Elsevier
Introduction Treatment options for second-generation (2 nd-gen) ALK tyrosine kinase
inhibitor (TKI)-resistant patients are limited. We evaluated the safety, pharmacokinetics, and …
inhibitor (TKI)-resistant patients are limited. We evaluated the safety, pharmacokinetics, and …
[HTML][HTML] Somatic KMT2D loss-of-function mutations in lung squamous cell carcinoma: a single-center cohort study
Z Fang, X Wu, L Xiao, C Wang, Y Zhao… - Journal of Thoracic …, 2024 - ncbi.nlm.nih.gov
Background The significant progress has been made in targeted therapy for lung
adenocarcinoma (LUAD) in the past decade. Only few targeted therapeutics have yet been …
adenocarcinoma (LUAD) in the past decade. Only few targeted therapeutics have yet been …
Pharmacokinetics, mass balance, and metabolism of [14C]envonalkib (TQ-B3139), a novel ALK tyrosine kinase inhibitor, in healthy Chinese subjects
S Ma, X Wang, S Yan, L Miao, X Wan, D Ding… - Cancer Chemotherapy …, 2024 - Springer
Abstract Purpose Envonalkib (TQ-B3139) is a novel, potent anaplastic lymphoma kinase
(ALK) tyrosine kinase inhibitor used to treat ALK-positive non-small cell lung cancer. This …
(ALK) tyrosine kinase inhibitor used to treat ALK-positive non-small cell lung cancer. This …
Unlocking the potential of oncology biomarkers: advancements in clinical theranostics
AK Dubey, I Kaur, R Madaan, S Raheja… - Drug Metabolism and …, 2024 - degruyter.com
Introduction Cancer biomarkers have revolutionized the field of oncology by providing
valuable insights into tumor changes and aiding in screening, diagnosis, prognosis …
valuable insights into tumor changes and aiding in screening, diagnosis, prognosis …